Fingernail lunula luminescence in COVID-19 patients: Is it a favipiravir-related reaction or a novel manifestation of coronavirus infection.
作者信息
Kutlu Ömer, Yılmaz Şule
机构信息
Department of Dermatology and Venereology, School of Medicine, Uşak University, Uşak, Turkey.
Department of Dermatology and Venereology, Antakya Private Laser Center, Hatay, Turkey.
出版信息
Photodermatol Photoimmunol Photomed. 2021 Jul;37(4):343-344. doi: 10.1111/phpp.12660. Epub 2021 Feb 3.
Abstract
摘要
相似文献
1
Fingernail lunula luminescence in COVID-19 patients: Is it a favipiravir-related reaction or a novel manifestation of coronavirus infection.新冠肺炎患者的指甲半月痕发光：是法匹拉韦相关反应还是冠状病毒感染的新表现？
Photodermatol Photoimmunol Photomed. 2021 Jul;37(4):343-344. doi: 10.1111/phpp.12660. Epub 2021 Feb 3.
2
Favipiravir, an antiviral for COVID-19?法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
3
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.一项评估法匹拉韦和羟氯喹联合治疗中重度 COVID-19 住院成人的疗效和安全性的随机对照研究：研究方案的结构化总结。
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
4
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.口服法匹拉韦治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA清除延迟患者：病例系列
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
5
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.新型冠状病毒病患者核酸检测由阴转阳的机制及临床转归和法匹拉韦的疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):488. doi: 10.1186/s13063-020-04430-y.
6
Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.将突变灾难视为一种潜在的新冠病毒治疗策略。
Heredity (Edinb). 2020 May;124(5):619-620. doi: 10.1038/s41437-020-0314-z. Epub 2020 Apr 6.
7
Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.关于法匹拉韦重新用于对抗新型冠状病毒的系统评价。
Mymensingh Med J. 2020 Jul;29(3):747-754.
8
Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey.土耳其伊兹密尔大学队列研究：使用法匹拉韦治疗 SARS-CoV-2 肺炎：初步结果。
Turk J Med Sci. 2021 Jun 28;51(3):912-920. doi: 10.3906/sag-2008-33.
9
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.一项针对 COVID-19 感染的抗病毒药物的适应性随机安慰剂对照 II 期试验（VIRCO）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 13;21(1):847. doi: 10.1186/s13063-020-04766-5.
10
A Favipiravir-induced Fever in a Patient with COVID-19.一名新冠肺炎患者出现法匹拉韦诱发的发热
Intern Med. 2020;59(22):2951-2953. doi: 10.2169/internalmedicine.5394-20. Epub 2020 Nov 15.
引用本文的文献
1
Follow-up of Favipiravir-Induced Nail Fluorescence: Implications for Nail and Drugs.法匹拉韦诱导的指甲荧光随访：对指甲和药物的影响
Dermatol Pract Concept. 2023 Jan 1;13(1):e2023011. doi: 10.5826/dpc.1301a11.
2
Onychomadesis in a COVID-19 patient.COVID-19 患者的甲脱落。
Wien Med Wochenschr. 2023 Sep;173(11-12):272-275. doi: 10.1007/s10354-022-00988-1. Epub 2022 Nov 28.
3
Evaluation of Nail Findings in Patients with COVID-19 History and Wood's Lamp Examination.对有新冠病毒疾病病史患者的指甲表现及伍德灯检查的评估
Skin Appendage Disord. 2021 Oct 12;38(2):1-6. doi: 10.1159/000518983.
Zotero 插件